

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 June 2008 (12.06.2008)

PCT

(10) International Publication Number
WO 2008/068266 A1

(51) International Patent Classification:

C07D 215/227 (2006.01) *C07D 215/12* (2006.01)
C07D 215/36 (2006.01) *C07D 407/04* (2006.01)
C07D 401/06 (2006.01) *A61K 31/47* (2006.01)
C07D 409/06 (2006.01) *A61P 31/04* (2006.01)

(21) International Application Number:

PCT/EP2007/063312

(22) International Filing Date:

4 December 2007 (04.12.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

06125546.9 6 December 2006 (06.12.2006) EP

(71) Applicant (for all designated States except US):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GUILLEMONT, Jérôme, Emile, Georges** [FR/FR]; Johnson & Johnson, Pharmaceutical Research and Development, A division of Janssen-Cilag, Campus de Maigremont BP615, F-27106 Val de Reuil Cedex (FR). **DORANGE, Ismet** [FR/SE]; Sickla alle, 21, S-13165 Nacka (SE). **ANDRIES, Koenraad, Jozef, Lodewijk, Marcel** [BE/BE]; Janssen

Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). **KOUL, Anil** [IN/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA N.V.**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.






(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: ANTIBACTERIAL QUINOLINE DERIVATIVES



(57) Abstract: The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): including any stereochemically isomeric form thereof, wherein Q represents a radical of formula a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compounds.



-
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- of inventorship (Rule 4.17(iv))

Published:

- with international search report